TRIP6 promotes inflammatory damage via the activation of TRAF6 signaling in a murine model of DSS-induced colitis

作者：Yun Yang, Xiu-Ming Li, Jingru Wang, Yan Li, Wen-Long Ye, Yi Wang, Yuxuan Liu, Zhiyong Deng, Wen-Juan Gan, Hua Wu · 发表于：Journal of Inflammation · 年份：2022 · DOI：10.1186/s12950-021-00298-0 · 被引用次数：10 · 研究领域：NF-κB Signaling Pathways、Inflammatory Bowel Disease、Protein Kinase Regulation and GTPase Signaling

Abstract Background TRIP6 is a zyxin family member that serves as an adaptor protein to regulate diverse biological processes. In prior reports, TRIP6 was shown to play a role in regulating inflammation. However, its in vivo roles and mechanistic importance in colitis remain largely elusive. Herein, we therefore employed TRIP6-deficient (TRIP6 −/− ) mice in order to explore the mechanistic importance of TRIP6 in a dextran sodium sulfate (DSS)-induced model of murine colitis. Findings Wild-type (TRIP6 +/+ ) mice developed more severe colitis following DSS-mediated disease induction relative to TRIP6 −/− mice, as evidenced by more severe colonic inflammation and associated crypt damage. TRIP6 expression in wild-type mice was significantly elevated following DSS treatment. Mechanistically, TRIP6 binds to TRAF6 and enhances oligomerization and autoubiquitination of TRAF6. This leads to the activation of NF-κB signaling and the expression of pro-inflammatory cytokines such as TNFα and IL-6, in the in vivo mouse model of colitis. Conclusions These in vivo data demonstrate that TRIP6 serves as a positive regulator of DSS-induced colitis through interactions with TRAF6 resulting in the activation of inflammatory TRAF6 signaling, highlighting its therapeutic promise as a protein that theoretically can be targeted to prevent or treat colitis.